Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Q: What equity inducement awards did Madrigal Pharmaceuticals (MDGL) grant on August 1, 2026?

Madrigal Pharmaceuticals granted an aggregate of 4,263 time-based restricted stock units to ten new non-executive employees. According to Madrigal Pharmaceuticals, these RSUs were granted as equity inducement awards under its 2025 Inducement Plan and approved by the independent Compensation Committee.

Q: How do the 2026 Madrigal Pharmaceuticals (MDGL) inducement RSUs vest for new employees?

The granted RSUs vest in four equal annual installments on the first through fourth anniversaries of the grant date. According to Madrigal Pharmaceuticals, vesting for each award is subject to the applicable employee’s continued employment on each vesting date.

Q: Why did Madrigal Pharmaceuticals (MDGL) use Nasdaq Listing Rule 5635(c)(4) for these inducement awards?

Madrigal Pharmaceuticals granted these awards under Nasdaq Listing Rule 5635(c)(4) as equity inducements material to accepting employment. According to Madrigal Pharmaceuticals, the independent Compensation Committee approved the grants under the company’s 2025 Inducement Plan.

Q: What conditions apply to vesting of Madrigal Pharmaceuticals (MDGL) August 2026 inducement RSUs?

Vesting is conditioned on each employee’s continued employment on the applicable vesting date. According to Madrigal Pharmaceuticals, the RSUs vest in four equal installments over four years, and unvested units depend on ongoing employment status.

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Very Positive)

Rhea-AI Summary

Madrigal Pharmaceuticals (NASDAQ:MDGL) granted equity inducement awards on August 1, 2026 to ten new non-executive employees under its 2025 Inducement Plan, approved by the independent Compensation Committee in line with Nasdaq Listing Rule 5635(c)(4). The employees received an aggregate of 4,263 time-based restricted stock units, vesting in four equal annual installments over four years, contingent on continued employment at each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

08/06/2026 - 04:05 PM

CONSHOHOCKEN, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on August 1, 2026 to ten new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

The equity awards were granted as an inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregate, 4,263 time-based restricted stock units. All restricted stock units granted vest in four equal installments on each of the first through fourth anniversaries of the grant date. The vesting of all awards described above shall be subject to each such employee’s continued employment as of the applicable vesting date.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra was the first medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com.

Investor Contact
Tina Ventura, IR@madrigalpharma.com

Media Contact
Christopher Frates, media@madrigalpharma.com

FAQ

What equity inducement awards did Madrigal Pharmaceuticals (MDGL) grant on August 1, 2026?

Madrigal Pharmaceuticals granted an aggregate of 4,263 time-based restricted stock units to ten new non-executive employees. According to Madrigal Pharmaceuticals, these RSUs were granted as equity inducement awards under its 2025 Inducement Plan and approved by the independent Compensation Committee.

How do the 2026 Madrigal Pharmaceuticals (MDGL) inducement RSUs vest for new employees?

The granted RSUs vest in four equal annual installments on the first through fourth anniversaries of the grant date. According to Madrigal Pharmaceuticals, vesting for each award is subject to the applicable employee’s continued employment on each vesting date.

Why did Madrigal Pharmaceuticals (MDGL) use Nasdaq Listing Rule 5635(c)(4) for these inducement awards?

Madrigal Pharmaceuticals granted these awards under Nasdaq Listing Rule 5635(c)(4) as equity inducements material to accepting employment. According to Madrigal Pharmaceuticals, the independent Compensation Committee approved the grants under the company’s 2025 Inducement Plan.

How many new employees received Madrigal Pharmaceuticals (MDGL) inducement awards in August 2026?

Ten new non-executive employees received the inducement awards from Madrigal Pharmaceuticals. According to Madrigal Pharmaceuticals, these employees were granted an aggregate of 4,263 time-based restricted stock units as a material inducement to accept employment with the company.

What conditions apply to vesting of Madrigal Pharmaceuticals (MDGL) August 2026 inducement RSUs?

Vesting is conditioned on each employee’s continued employment on the applicable vesting date. According to Madrigal Pharmaceuticals, the RSUs vest in four equal installments over four years, and unvested units depend on ongoing employment status.